Incendia Therapeutics
Sumita Roy is an experienced professional in operations and management within the biotechnology and pharmaceutical sectors. Currently serving as Senior Director of Operations, Facilities, Procurement, and Lab Operations at Incendia Therapeutics since April 2024, Sumita previously held significant roles at SOTIO as Director of Internal Operations and at Unum Therapeutics as Associate Director of Internal Operations. Additional experience includes managing laboratory and facility operations at Editas Medicine and AVEO Oncology, as well as consulting positions at Novartis and T2 Biosystems. Earlier career accomplishments feature leadership in biorepository operations at Brigham and Women's Hospital and extensive research laboratory management at Curis, Inc. and Genzyme Genetics.
Incendia Therapeutics
Incendia Therapeutics is discovering and developing novel anti-cancer medicines that are designed to reprogram the tumor microenvironment. Many cancers create immune exclusion barriers that prevent the immune system from attacking tumors. The Parthenon approach to overcoming these barriers is to modulate the interplay among cancer cells, stromal cells, and immune cells. Our lead program, PRTH-101, is a first-in-class humanized monoclonal antibody that blocks the interaction of Discoidin Domain Receptor 1 (DDR1) with collagen, thereby “punching holes” in the extracellular matrix barrier created by the tumor. With the extracellular matrix barrier breached, immune cells are able to infiltrate and attack the tumor. PRTH-101 is poised to enter Phase 1 clinical trials. PRTH-101 is followed by a pipeline of preclinical projects targeting orthogonal components of the tumor microenvironment that promote immune exclusion. Incendia combines its drug discovery and development efforts with a precision oncology approach to get the right medicines to the right patients. We use proprietary AI technology to digitally deconstruct the TME and develop unique insights to enable biomarker-driven patient selection strategies designed to guide clinical applications.